JP2024538148A5 - - Google Patents

Info

Publication number
JP2024538148A5
JP2024538148A5 JP2024522646A JP2024522646A JP2024538148A5 JP 2024538148 A5 JP2024538148 A5 JP 2024538148A5 JP 2024522646 A JP2024522646 A JP 2024522646A JP 2024522646 A JP2024522646 A JP 2024522646A JP 2024538148 A5 JP2024538148 A5 JP 2024538148A5
Authority
JP
Japan
Prior art keywords
sequence number
chain sequence
heavy chain
seq
light chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024522646A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024538148A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/078192 external-priority patent/WO2023069888A1/en
Publication of JP2024538148A publication Critical patent/JP2024538148A/ja
Publication of JP2024538148A5 publication Critical patent/JP2024538148A5/ja
Pending legal-status Critical Current

Links

JP2024522646A 2021-10-18 2022-10-17 抗ＥＧＦＲ抗体、抗ｃＭＥＴ抗体、抗ＶＥＧＦ抗体、多重特異性抗体及びそれらの使用 Pending JP2024538148A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163256705P 2021-10-18 2021-10-18
US63/256,705 2021-10-18
PCT/US2022/078192 WO2023069888A1 (en) 2021-10-18 2022-10-17 ANTI-EGFR ANTIBODIES, ANTI-cMET ANTIBODIES, ANTI-VEGF ANTIBODIES, MULTISPECIFIC ANTIBODIES, AND USES THEREOF

Publications (2)

Publication Number Publication Date
JP2024538148A JP2024538148A (ja) 2024-10-18
JP2024538148A5 true JP2024538148A5 (enExample) 2025-10-22

Family

ID=84267971

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024522646A Pending JP2024538148A (ja) 2021-10-18 2022-10-17 抗ＥＧＦＲ抗体、抗ｃＭＥＴ抗体、抗ＶＥＧＦ抗体、多重特異性抗体及びそれらの使用

Country Status (8)

Country Link
US (1) US20250230248A1 (enExample)
EP (1) EP4419556A1 (enExample)
JP (1) JP2024538148A (enExample)
KR (1) KR20240099227A (enExample)
CN (1) CN118355030A (enExample)
AU (1) AU2022369278A1 (enExample)
CA (1) CA3232216A1 (enExample)
WO (1) WO2023069888A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4454705A1 (en) * 2023-04-28 2024-10-30 Jost B. Jonas Egfr antagonists for the treatment of diseases involving unwanted migration, proliferation, and metaplasia of retinal pigment epithelium (rpe) cells
WO2025056713A1 (en) * 2023-09-12 2025-03-20 Jonas Jost B Egfr antagonists for the treatment of diseases involving unwanted migration, proliferation, and/or metaplasia of retinal pigment epithelium (rpe) cells
WO2025108427A1 (zh) * 2023-11-23 2025-05-30 橙帆生物医药公司 结合分子及抗体药物偶联物和用途
CN118085101A (zh) * 2024-03-01 2024-05-28 烟台蓝纳成生物技术有限公司 一种二价双特异性抗体、抗体偶联核素药物及其应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2156149T3 (es) 1992-12-04 2001-06-16 Medical Res Council Proteinas de union multivalente y multiespecificas, su fabricacion y su uso.
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
WO2006028936A2 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
AU2006232287B2 (en) 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
WO2007042289A2 (en) * 2005-10-11 2007-04-19 Ablynx N.V. Nanobodies™ and polypeptides against egfr and igf-ir
JP2009541275A (ja) 2006-06-22 2009-11-26 ノボ・ノルデイスク・エー／エス 二重特異性抗体の生産
EP2417164A1 (en) 2009-04-07 2012-02-15 Roche Glycart AG Bispecific anti-erbb-2/anti-c-met antibodies
WO2010129304A2 (en) 2009-04-27 2010-11-11 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
JP6219287B2 (ja) * 2011-09-30 2017-10-25 アブリンクス エン．ヴェー． ｃ−Ｍｅｔに関連する生物学的物質
US20170275367A1 (en) 2012-11-21 2017-09-28 Janssen Biotech, Inc. Bispecific EGFR/C-Met Antibodies
MX361088B (es) * 2012-11-21 2018-11-26 Janssen Biotech Inc Anticuerpos del receptor del factor de crecimiento epidérmico aislado/del receptor del factor de crecimiento de hepatocitos (egfr/c-met) biespecíficos.
KR102089591B1 (ko) * 2013-07-29 2020-03-18 삼성전자주식회사 항 EGFR scFv 단편 및 이를 포함하는 항 c-Met/항 EGFR 이중 특이 항체
ES2751279T3 (es) 2014-11-27 2020-03-31 Panasonic Ip Man Co Ltd Unidad de panel de vidrio
CN108350078A (zh) 2015-11-03 2018-07-31 默克专利股份公司 用于提高肿瘤选择性和抑制的双特异性抗体及其用途

Similar Documents

Publication Publication Date Title
JP2024538148A5 (enExample)
JP2021514664A5 (enExample)
JP2022526764A5 (enExample)
JP2021526022A5 (enExample)
IL276830B1 (en) Anti-claudin 18.2 antibodies and their uses
KR102078292B1 (ko) 신규한 항 c-Met 항체 및 이의 용도
JP2024531409A5 (enExample)
JP2017149720A5 (enExample)
JP2017514461A5 (enExample)
HRP20192038T1 (hr) Protutijela receptora anti-epidermalnog faktora rasta (egfr)
JP2020501598A5 (enExample)
CN114761433B (zh) 一种抗Claudin18.2单克隆抗体、其制备方法及用途
JP2020522281A5 (enExample)
JP2020522280A5 (enExample)
JP2021528400A5 (enExample)
JP2022533538A5 (enExample)
JP2017521054A5 (enExample)
JP2021517459A5 (enExample)
JP2025501775A5 (enExample)
JP2024024114A5 (enExample)
JP2024540148A5 (enExample)
JP2021512652A5 (enExample)
TW202241944A (zh) 新穎的抗ｇｒｅｍｌｉｎ１抗體
JP2021518390A5 (enExample)
JP2018528759A5 (enExample)